↓ Skip to main content

Dove Medical Press

Acromegaly: the disease, its impact on patients, and managing the burden of long-term treatment

Overview of attention for article published in International Journal of General Medicine, January 2013
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (72nd percentile)
  • Good Attention Score compared to outputs of the same age and source (69th percentile)

Mentioned by

twitter
1 X user
patent
10 patents
facebook
1 Facebook page

Readers on

mendeley
115 Mendeley
Title
Acromegaly: the disease, its impact on patients, and managing the burden of long-term treatment
Published in
International Journal of General Medicine, January 2013
DOI 10.2147/ijgm.s38594
Pubmed ID
Authors

Daphne T Adelman, Karen JP Liebert, Lisa B Nachtigall, Michele Lamerson, Bert Bakker

Abstract

Acromegaly is a rare disease most often caused by the prolonged secretion of excess growth hormone from a pituitary adenoma. The disease is associated with multiple significant comorbidities and increased mortality. The delay to diagnosis is often long. This may be because of low disease awareness among health care professionals, the insidious onset of differentiating features, and because patients are likely to present with complaints typical of other conditions more frequently seen in primary care. Early identification of acromegaly facilitates prompt treatment initiation and may minimize the permanent effects of excess growth hormone. The primary treatment for many patients will be pituitary surgery, although not all patients will be eligible for surgery or achieve a surgical cure. If biochemical control is not achieved following surgery, other treatment options include medical therapy and radiation therapy. Improved biochemical control may only alleviate rather than reverse the associated comorbidities. Thus, lifelong monitoring of patient health is needed, with particular attention to the management of cardiovascular risk factors. It is additionally important to consider the impact of both disease and treatment on patients' quality of life and minimize that impact where possible, but particularly for chronic therapies. For the majority of patients, chronic therapy is likely to include somatostatin analog injections. In some circumstances, it may be possible to extend the dosing interval of the analog once good biochemical control is achieved. Additional convenience may be gained from the possibility of self-/partner administration of treatment or administration of treatment by a health care professional at home. Overall, it is clear that the care of patients with acromegaly requires a highly coordinated approach involving numerous specialties (eg, endocrinology, surgery, cardiology). Further, patients' needs must be at the core of management and every effort must be made to improve health care experiences and minimize treatment burdens.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 115 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Canada 1 <1%
Unknown 114 99%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 19 17%
Researcher 16 14%
Student > Master 16 14%
Other 11 10%
Student > Ph. D. Student 10 9%
Other 17 15%
Unknown 26 23%
Readers by discipline Count As %
Medicine and Dentistry 47 41%
Biochemistry, Genetics and Molecular Biology 12 10%
Psychology 6 5%
Agricultural and Biological Sciences 5 4%
Pharmacology, Toxicology and Pharmaceutical Science 5 4%
Other 14 12%
Unknown 26 23%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 February 2024.
All research outputs
#7,666,122
of 25,134,448 outputs
Outputs from International Journal of General Medicine
#371
of 1,626 outputs
Outputs of similar age
#78,691
of 293,733 outputs
Outputs of similar age from International Journal of General Medicine
#5
of 13 outputs
Altmetric has tracked 25,134,448 research outputs across all sources so far. This one has received more attention than most of these and is in the 69th percentile.
So far Altmetric has tracked 1,626 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.0. This one has done well, scoring higher than 76% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 293,733 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.